2023. Circulating Tumour DNA for Minimal Residual Disease: Assay Sensitivity and the Decisions It Cannot Yet Support. Translational Medicine & Therapeutics Journal. 2, 2 (Dec. 2023), 110–119. DOI:https://doi.org/10.5281/zenodo.22649122.